{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T19:42:13Z","timestamp":1708026133450},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2001,6]]},"DOI":"10.1007\/s11864-001-0041-5","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T20:43:58Z","timestamp":1183581838000},"page":"271-283","source":"Crossref","is-referenced-by-count":10,"title":["Bone disease in myeloma"],"prefix":"10.1007","volume":"2","author":[{"given":"James R.","family":"Berenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"41_CR1","first-page":"291","volume":"13","author":"GR Mundy","year":"1986","unstructured":"Mundy GR, Bertoline DR: Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986, 13:291\u2013299.","journal-title":"Semin Oncol"},{"key":"41_CR2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","volume":"9","author":"AR Belch","year":"1991","unstructured":"Belch AR, Bergsagel DE, Wilson K, et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397\u20131402.","journal-title":"J Clin Oncol"},{"key":"41_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1056\/NEJM197512252932602","volume":"293","author":"RA Kyle","year":"1975","unstructured":"Kyle RA, Jowsey J, Kelly PJ, et al.: Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975, 293:1334\u20131338.","journal-title":"N Engl J Med"},{"key":"41_CR4","first-page":"29","volume":"50","author":"RA Kyle","year":"1975","unstructured":"Kyle RA: Multiple myeloma, review of 869 cases. Mayo Clin Proc 1975, 50:29\u201340.","journal-title":"Mayo Clin Proc"},{"key":"41_CR5","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.4049\/jimmunol.138.5.1464","volume":"138","author":"P Stashenko","year":"1987","unstructured":"Stashenko P, Dewhirst FE, Peros WJ, et al.: Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987, 138:1464\u20131468.","journal-title":"J Immunol"},{"key":"41_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/8756-3282(91)90057-P","volume":"12","author":"GR Mundy","year":"1991","unstructured":"Mundy GR: Mechanisms of osteolytic bone destruction. Bone 1991, 12(suppl):S1-S6.","journal-title":"Bone"},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","volume":"90","author":"R Bataille","year":"1995","unstructured":"Bataille R, Chappard D, Basle M: Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995, 90:721\u2013724.","journal-title":"Br J Haematol"},{"key":"41_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.med.50.1.237","volume":"50","author":"JR Berenson","year":"1999","unstructured":"Berenson JR, Lipton A: Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999, 50:237\u2013248. This article reviews clinical trials involving bisphosphonates in the treatment of bone metastases.","journal-title":"Annu Rev Med"},{"key":"41_CR9","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/8756-3282(91)90061-M","volume":"12","author":"JA Kanis","year":"1991","unstructured":"Kanis JA, McCloskey EV, Taube T, et al.: Rationale for the use of bisphosphonates in bone metastases. Bone 1991, 12(suppl):S13-S18.","journal-title":"Bone"},{"key":"41_CR10","first-page":"12","volume-title":"Recent Results in Cancer Research, Vol. 116: Bisphosphonates and Tumor Osteolysis","author":"H Fleisch","year":"1989","unstructured":"Fleisch H: Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In Recent Results in Cancer Research, Vol. 116: Bisphosphonates and Tumor Osteolysis. Edited by Brunner KW, Fleisch H, Senn H-J. Berlin: Springer-Verlag; 1989:12\u201328."},{"key":"41_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","volume":"340","author":"R Lahtinen","year":"1992","unstructured":"Lahtinen R, Laakso M, Palva I, et al.: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049\u20131052.","journal-title":"Lancet"},{"key":"41_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0140-6736(90)90452-B","volume":"335","author":"Z Man","year":"1990","unstructured":"Man Z, Otero AB, Rendo P, et al.: Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990, 335:663.","journal-title":"Lancet"},{"key":"41_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0277-5379(91)90056-J","volume":"27","author":"D Thiebaud","year":"1991","unstructured":"Thiebaud D, Leyuraz S, Von Fliedner V, et al.: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991, 27:37\u201341.","journal-title":"Eur J Cancer"},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","volume":"70","author":"OP Purohit","year":"1994","unstructured":"Purohit OP, Anthony C, Radstone CR, et al.: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994, 70:554\u2013558.","journal-title":"Br J Cancer"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","volume":"11","author":"AATM van Holten-Verzantvoort","year":"1993","unstructured":"van Holten-Verzantvoort AATM, Kroon HM, Bijvoet OLM, et al.: Palliative treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:491\u2013498.","journal-title":"J Clin Oncol"},{"key":"41_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","volume":"101","author":"EV McCloskey","year":"1998","unstructured":"McCloskey EV, MacLennan CM, Drayson MT, et al.:A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998, 101:317\u2013325.","journal-title":"Br J Haematol"},{"key":"41_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000218633","volume":"18","author":"ME Heim","year":"1995","unstructured":"Heim ME, Clemens MR, Queisser W, et al.:Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 1995, 18:439\u2013448.","journal-title":"Onkologie"},{"key":"41_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","volume":"101","author":"H Brincker","year":"1998","unstructured":"Brincker H, Westin J, Abildgaard U, et al.: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998, 101:280\u2013286.","journal-title":"Br J Haematol"},{"key":"41_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488\u2013493.","journal-title":"N Engl J Med"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"J Berenson","year":"1998","unstructured":"Berenson J, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593\u2013602.","journal-title":"J Clin Oncol"},{"key":"41_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/0268-960X(91)90039-F","volume":"5","author":"NP Rowell","year":"1991","unstructured":"Rowell NP, Tobias JS: The role of radiotherapy in the management of multiple myeloma. Blood Rev 1991, 5:84\u201389.","journal-title":"Blood Rev"},{"key":"41_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hon.2900060221","volume":"6","author":"AY Rostom","year":"1988","unstructured":"Rostom AY: A review of the place of radiotherapy in myeloma with emphasis on whole body irradiation. Hematol Oncol 1988, 6:193\u2013198.","journal-title":"Hematol Oncol"},{"key":"41_CR23","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/0959-8049(92)90527-9","volume":"28A","author":"FJ Giles","year":"1992","unstructured":"Giles FJ, McSweeney EN, Richards JDM, et al.:Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. Eur J Cancer 1992, 28A:1392\u20131395.","journal-title":"Eur J Cancer"},{"key":"41_CR24","first-page":"558a","volume":"96","author":"S Giralt","year":"2000","unstructured":"Giralt S, Champlin R, Goodman M, et al.: Preliminary results of a phase I\/II study of multiple myeloma (MM) patients treated with 166holmium-DOTMP in combination with high dose melphalan +\/- total body irradiation (TBI) with autologous stem cell transplant (ASCT). Blood 2000, 96:558a.","journal-title":"Blood"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V63.3.639.639","volume":"63","author":"HJ Cohen","year":"1984","unstructured":"Cohen HJ, Silberman HR, Tornyos K, et al.: Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 1984, 63:639\u2013648.","journal-title":"Blood"},{"key":"41_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1056\/NEJM197206152862402","volume":"286","author":"Acute Leukemia Group B, Eastern Cooperative Oncology Group B","year":"1972","unstructured":"Acute Leukemia Group B, Eastern Cooperative Oncology Group B: Ineffectiveness of fluoride therapy in multiple myeloma. N Engl J Med 1972, 286:1283\u20131288.","journal-title":"N Engl J Med"},{"key":"41_CR27","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.1993.11.12.2443","volume":"11","author":"RP Warrell","year":"1993","unstructured":"Warrell RP, Lovett D, Dilmanian A, et al.: Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993, 11:2443\u20132450.","journal-title":"J Clin Oncol"},{"key":"41_CR28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558\u2013567. This clinical trial provides the first clear data showing the superiority of a third-generation bisphosphonate over pamidronate.","journal-title":"J Clin Oncol"},{"key":"41_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/er.19.1.80","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80\u2013100. An excellent review of the mechanisms of action of bisphosphonates.","journal-title":"Endocr Rev"},{"key":"41_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/sj.leu.2400892","volume":"12","author":"A Aparicio","year":"1998","unstructured":"Aparicio A, Gardner A, Tu Y, et al.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220\u2013229.","journal-title":"Leukemia"},{"key":"41_CR31","first-page":"5294","volume":"58","author":"CM Shipman","year":"1998","unstructured":"Shipman CM, Croucher PI, Russell GG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294\u20135297.","journal-title":"Cancer Res"},{"key":"41_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","volume":"13","author":"SP Luckman","year":"1998","unstructured":"Luckman SP, Hughes DE, Coxon FP, et al.: Nitrogencontaining bisphosphonates inhibit the mevalonic pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 1998, 13:581\u2013589.","journal-title":"J Bone Miner Res"},{"key":"41_CR33","first-page":"6001","volume":"60","author":"GG Reinholz","year":"2000","unstructured":"Reinholz GG, Getz B, Pederson L, et al.: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001\u20136007.","journal-title":"Cancer Res"},{"key":"41_CR34","first-page":"105a","volume":"88","author":"AD Savage","year":"1996","unstructured":"Savage AD, Belson DJ, Vescio RA, et al.: Pamidronate reduces IL-6 production by bone marrow stroma from myeloma patients. Blood 1996, 88:105a.","journal-title":"Blood"},{"key":"41_CR35","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","volume":"14","author":"S Derenne","year":"1999","unstructured":"Derenne S, Amiot M, Barille S, et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMp-1 by the tumoral environment. J Bone Miner Res 1999, 14:2048\u20132056.","journal-title":"J Bone Miner Res"},{"key":"41_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/030097498441155","volume":"27","author":"N Giuliani","year":"1998","unstructured":"Giuliani N, Pedrazzoni M, Passeri G, et al.: Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998, 27:38.","journal-title":"Scand J Rheumatol"},{"key":"41_CR37","first-page":"664a","volume":"19","author":"J Wood","year":"2000","unstructured":"Wood J, Schnell C, Green J: Zoledronic acid (Zometa), a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. Proc Am Soc Clin Oncol 2000, 19:664a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"41_CR38","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565\u20131561.","journal-title":"N Engl J Med"},{"key":"41_CR39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, Bauer E, Feurle J, et al.: Stimulation of gdT cells by aminobisphosphonate and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384\u2013392.","journal-title":"Blood"},{"key":"41_CR40","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","volume":"55","author":"J Radl","year":"1985","unstructured":"Radl J, Croese JW, Zurcher C, et al.: Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985, 55:1030\u20131040.","journal-title":"Cancer"},{"key":"41_CR41","doi-asserted-by":"crossref","first-page":"106a","DOI":"10.1182\/blood.V92.8.2908","volume":"92","author":"S Yaccoby","year":"1998","unstructured":"Yaccoby S, Barlogie B, Epstein J: Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system. Blood 1998, 92:106a.","journal-title":"Blood"},{"key":"41_CR42","first-page":"549a","volume":"96","author":"S Yaccoby","year":"2000","unstructured":"Yaccoby S, Pearse R, Epstein J, et al.: Reciprocal relationship between myeloma-induced changes in the bone marrow microenvironment and myeloma cell growth. Blood 2000, 96:549a.","journal-title":"Blood"},{"key":"41_CR43","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","volume":"93","author":"SL Dallas","year":"1999","unstructured":"Dallas SL, Garrett IR, Oyajobi BO, et al.: Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697\u20131706.","journal-title":"Blood"},{"key":"41_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0221-8747(82)90013-3","volume":"4","author":"PD Delmas","year":"1982","unstructured":"Delmas PD, Charhon S, Chapuy MC, et al.: Long-term effects of dichloromethylene diphosphonate (C12MDP) on skeletal lesions in multiple myeloma. Metabolic Bone Dis Related Res 1982, 4:163\u2013168.","journal-title":"Metabolic Bone Dis Related Res"},{"key":"41_CR45","first-page":"2127","volume":"90","author":"G Merlini","year":"1990","unstructured":"Merlini G, Parrinello GA, Piccinini L, et al.: Long-term effects of parenteral dichloromethylene bisphosphonate (C12MDP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990, 90:2127\u20132147.","journal-title":"Hematol Oncol"},{"key":"41_CR46","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","volume":"131","author":"P Ravn","year":"1999","unstructured":"Ravn P, Bidstrup M, Wasnich RD, et al.: Alendronate and estrogen-progestin the long-term prevention of bone loss: four-year results from the early postmenopausal osteoporosis intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999, 131:935\u2013942.","journal-title":"Ann Intern Med"},{"key":"41_CR47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","volume":"37","author":"J Berenson","year":"1997","unstructured":"Berenson J, Rosen L, Vescio R, et al.: Pharmacokinetics of pamidronate disodium in cancer patients with normal and impaired renal dysfunction. J Clin Pharmacol 1997, 37:285\u2013290.","journal-title":"J Clin Pharmacol"},{"key":"41_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","volume":"6","author":"RC Muhlbacher","year":"1991","unstructured":"Muhlbacher RC, Bauss F, Schenk R, et al.: BM.21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6:1003.","journal-title":"J Bone Miner Res"},{"key":"41_CR49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42\u2019446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9:745\u2013750.","journal-title":"J Bone Miner Res"},{"key":"41_CR50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1996.14.1.268","volume":"14","author":"M Percherstorfer","year":"1996","unstructured":"Percherstorfer M, Herrmann Z, Body JJ, et al.: Randomized phase II trial comparing different doses of the bisphosphonate idbandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14:268\u2013276.","journal-title":"J Clin Oncol"},{"key":"41_CR51","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1359\/jbmr.1999.14.9.1557","volume":"14","author":"JJ Body","year":"1999","unstructured":"Body JJ, Lortholary A, Romieu G, et al.: A dose-finding study of Zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999, 14:1551\u20131661.","journal-title":"J Bone Miner Res"},{"key":"41_CR52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q","volume":"91","author":"J Berenson","year":"2001","unstructured":"Berenson J, Vescio R, Henick K, et al.: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001, 91:144\u2013154.","journal-title":"Cancer"},{"key":"41_CR53","unstructured":"Berenson J, Vescio R, Rosen L, et al.: A phase I doseranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001, In press."},{"key":"41_CR54","doi-asserted-by":"crossref","unstructured":"Berenson J, Rosen LS, Howell A, et al.: Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001, In press.","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0"},{"key":"41_CR55","first-page":"106a","volume":"92","author":"A Fontana","year":"1998","unstructured":"Fontana A, Hermann Z, Menssen HD, et al.: Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival inpatients with advanced multiple myeloma. Blood 1998, 92:106a.","journal-title":"Blood"},{"key":"41_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/eje.0.1410195","volume":"141","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC: Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Soc Eur J Endocrinol 1999, 141:195\u2013210. This article provides a review of the RANK, RANK ligand, and OPG molecules.","journal-title":"Soc Eur J Endocrinol"},{"key":"41_CR57","doi-asserted-by":"crossref","first-page":"365a","DOI":"10.1182\/blood.V96.1.365","volume":"96","author":"CV Altamirano","year":"2000","unstructured":"Altamirano CV, Ma HJ, Parker KM, et al.: RANKL is expressed in malignant multiple myeloma (MM) cell lines. Blood 2000, 96:365a.","journal-title":"Blood"},{"key":"41_CR58","first-page":"360a","volume":"96","author":"CM Shipman","year":"2000","unstructured":"Shipman CM, Holen I, Lippitt JM, et al.: Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 2000, 96:360a.","journal-title":"Blood"},{"key":"41_CR59","first-page":"783","volume":"60","author":"C Capparelli","year":"2000","unstructured":"Capparelli C, Kostenuik PJ, Morony S, et al.:Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000, 60:783\u2013787.","journal-title":"Cancer Res"},{"key":"41_CR60","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/74999","volume":"6","author":"P Honore","year":"2000","unstructured":"Honore P, Luger NM, Sabino MAC, et al.: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6:521\u2013528.","journal-title":"Nat Med"},{"key":"41_CR61","first-page":"549a","volume":"96","author":"RN Pearse","year":"2000","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, et al.: Administration of TRANCE-antagonist TR-Fc limits myeloma-induced bone destruction. Blood 2000, 96:549a.","journal-title":"Blood"},{"key":"41_CR62","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/nm1197-1285","volume":"11","author":"V Iotsova","year":"1997","unstructured":"Iotsova V, Caamano J, Loy J, et al.: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 11:1285\u20131289.","journal-title":"Nat Med"},{"key":"41_CR63","first-page":"6557","volume":"60","author":"VB Andela","year":"2000","unstructured":"Andela VB, Schwarz EM, Puzas E, et al.: Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kB. Cancer Res 2000, 60:6557\u20136562.","journal-title":"Cancer Res"},{"key":"41_CR64","first-page":"516a","volume":"96","author":"TE Stinchcombe","year":"2000","unstructured":"Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al.:PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood 2000, 96:516a.","journal-title":"Blood"},{"key":"41_CR65","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","volume":"286","author":"G Mundy","year":"1999","unstructured":"Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946\u20131949. This preclinical study suggests the possible usefulness of statins in increasing bone density.","journal-title":"Science"},{"key":"41_CR66","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1126\/science.289.5484.1498","volume":"289","author":"RF Service","year":"2000","unstructured":"Service RF: Tissue engineers build new bone. Science 2000, 289:1498\u20131499.","journal-title":"Science"},{"key":"41_CR67","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1172\/JCI119404","volume":"99","author":"VW Engleman","year":"1997","unstructured":"Engleman VW, Nickols GA, Ross FP, et al.: A peptidomimetic antagonist of the avb3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997, 99:2284\u20132292.","journal-title":"J Clin Invest"},{"key":"41_CR68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1677\/joe.0.1650587","volume":"165","author":"CP Carron","year":"2000","unstructured":"Carron CP, Myer DM, Engleman VW, et al.: Peptidomimetic antagonist of aVb3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 2000, 165:587\u2013598.","journal-title":"J Endocrinol"},{"key":"41_CR69","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.7512751","volume":"264","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569.","journal-title":"Science"},{"key":"41_CR70","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1172\/JCI118227","volume":"96","author":"PC Brooks","year":"1995","unstructured":"Brooks PC, Stromblad S, Klemke R, et al.: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815.","journal-title":"J Clin Invest"},{"key":"41_CR71","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/j.1460-2075.1995.tb07072.x","volume":"14","author":"J Ray","year":"1995","unstructured":"Ray J, Stetler-Stevenson W: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995, 14:908.","journal-title":"EMBO J"},{"key":"41_CR72","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1172\/JCI119435","volume":"99","author":"T Yoneda","year":"1997","unstructured":"Yoneda T, Sasaki A, Dunstan C, et al.: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997, 99:2509\u20132517.","journal-title":"J Clin Invest"},{"key":"41_CR73","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064.409k07_3064_3073","volume":"93","author":"A Vacca","year":"1999","unstructured":"Vacca A, Ribatta D, Preta M, et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064\u20133073.","journal-title":"Blood"},{"key":"41_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1073\/pnas.011343298","volume":"98","author":"S Silletti","year":"2001","unstructured":"Silletti S, Kessler T, Goldberg J, et al.: Disruption of matrix metalloproteinase 2 binding to integrin aVb3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Nat Acad Sci U S A 2001, 98:119\u2013124.","journal-title":"Proc Nat Acad Sci U S A"},{"key":"41_CR75","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1101\/gad.11.21.2835","volume":"11","author":"PL Schwartzberg","year":"1997","unstructured":"Schwartzberg PL, Xing L, Hoffmann O, et al.: Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-\/-mutant mice. Genes Dev 1997, 11:2835\u20132834.","journal-title":"Genes Dev"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-001-0041-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0041-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0041-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T19:04:10Z","timestamp":1708023850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-001-0041-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11864-001-0041-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}